Jan 17, 2019 7:05am EST First Patient Dosed in Phase 1 Clinical Trial Evaluating Neoepitopes Formulated in IMV’s DPX Delivery Platform in Ovarian Cancer Patients
Dec 13, 2018 4:05am EST IMV Inc. Presents Updated Positive Data From Phase 1b/2 Combination Clinical Trial in Advanced Ovarian Cancer at 2018 ESMO Immuno-Oncology Congress
Dec 10, 2018 7:05am EST IMV Announces Updated Clinical Data Presentation for Lead Candidate DPX-Survivac’s Phase 1b/2 Immunotherapy Combination Trial at the ESMO Immuno-Oncology Congress 2018
Dec 05, 2018 7:05am EST IMV Welcomes Marc Jasmin as Senior Director, Investor Relations and Communications
Nov 26, 2018 4:35pm EST IMV Leadership to Present Respiratory Syncytial Virus (RSV) Research at RespiDART 2018
Nov 20, 2018 7:05am EST IMV Moves to Develop DPX-Survivac as Monotherapy for Recurrent Ovarian Cancer
Nov 06, 2018 7:05am EST Veteran Oncology Biotechnology Executive and Third Rock Ventures Entrepreneur in Residence Markus Warmuth, MD, Joins IMV Inc. Board of Directors
Nov 02, 2018 7:05am EDT IMV Inc. Announces Q3 2018 Financial Results and Investor Conference Call Details
